

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06823167

Status	RECRUITING
Phase	Phase 1
Sponsor	Immunome, Inc.
Enrollment	117 participants

Key Eligibility Criteria

Inclusion (24)

- Informed consent signed by the participant prior to conducting study-specific procedures
- e18years of age
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Histological or cytological diagnosis of:
- Part A: advanced B-cell lymphomas or solid tumors, of the following subtypes:
... and 19 more (see full listing online)

Exclusion (10)

- Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.
- Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).
- History of an anaphylactic reaction to irinotecan or e grade 3 GI toxicity to prior irinotecan.
- Life expectancy \< 12 weeks.
- Prior solid organ transplant.
... and 5 more (see full listing online)

Locations (12 total)

City Of Hope, Duarte, California, United States
Yale University Medical Center, New Haven, Connecticut, United States
Emory Winship Cancer Institute, Atlanta, Georgia, United States
... and 9 more locations